Specifically, we demonstrated how features associated with PB, such as diabetes, could not only blunt skeletal muscle growth independently via reduced insulin signaling but also potentially influence other physiological processes (i.e., metabolite-mediated changes in autophagy gene expression) known to mediate skeletal muscle growth (i.e., increases in inflammation via reductions in autophagy). The gene discussed is INS; the disease is diabetes mellitus.